PharVision Advisers LLC Makes New $366,000 Investment in The Charles Schwab Co. (NYSE:SCHW)

PharVision Advisers LLC acquired a new stake in The Charles Schwab Co. (NYSE:SCHW - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,950 shares of the financial services provider's stock, valued at approximately $366,000.

A number of other hedge funds have also made changes to their positions in SCHW. Arkadios Wealth Advisors lifted its holdings in shares of Charles Schwab by 10.2% in the fourth quarter. Arkadios Wealth Advisors now owns 11,864 shares of the financial services provider's stock valued at $878,000 after buying an additional 1,099 shares during the period. Ameritas Advisory Services LLC acquired a new position in Charles Schwab during the fourth quarter worth about $422,000. UMB Bank n.a. raised its position in Charles Schwab by 4.7% in the fourth quarter. UMB Bank n.a. now owns 21,285 shares of the financial services provider's stock worth $1,575,000 after acquiring an additional 964 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Charles Schwab by 8.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 5,424 shares of the financial services provider's stock worth $401,000 after acquiring an additional 437 shares in the last quarter. Finally, Leonard Rickey Investment Advisors P.L.L.C. lifted its holdings in Charles Schwab by 23.1% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 10,193 shares of the financial services provider's stock valued at $754,000 after acquiring an additional 1,912 shares during the last quarter. Institutional investors and hedge funds own 84.38% of the company's stock.

Charles Schwab Price Performance

Shares of SCHW opened at $89.13 on Wednesday. The business's 50-day moving average is $79.37 and its 200-day moving average is $78.67. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.47 and a quick ratio of 0.47. The company has a market capitalization of $161.95 billion, a price-to-earnings ratio of 29.81, a P/E/G ratio of 0.99 and a beta of 0.90. The Charles Schwab Co. has a fifty-two week low of $61.01 and a fifty-two week high of $89.87.

Charles Schwab (NYSE:SCHW - Get Free Report) last released its earnings results on Thursday, April 17th. The financial services provider reported $1.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.01 by $0.03. Charles Schwab had a net margin of 30.31% and a return on equity of 18.20%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.46 billion. During the same quarter in the prior year, the firm earned $0.74 EPS. Equities research analysts expect that The Charles Schwab Co. will post 4.22 EPS for the current fiscal year.

Charles Schwab Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 23rd. Stockholders of record on Friday, May 9th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.08 annualized dividend and a dividend yield of 1.21%. Charles Schwab's dividend payout ratio is 32.73%.

Analyst Ratings Changes

A number of research firms recently commented on SCHW. Barclays dropped their target price on shares of Charles Schwab from $96.00 to $84.00 and set an "overweight" rating on the stock in a report on Monday, April 7th. JMP Securities restated a "market outperform" rating and issued a $94.00 price target on shares of Charles Schwab in a research report on Monday, April 21st. The Goldman Sachs Group upgraded Charles Schwab from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Friday, April 25th. Piper Sandler raised their price objective on Charles Schwab from $74.00 to $80.00 in a research note on Thursday, April 17th. Finally, TD Securities lifted their target price on Charles Schwab from $95.00 to $113.00 and gave the stock a "buy" rating in a report on Tuesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Charles Schwab has an average rating of "Moderate Buy" and a consensus price target of $89.63.

Insider Activity at Charles Schwab

In related news, Director Frank C. Herringer sold 3,592 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $74.26, for a total value of $266,741.92. Following the transaction, the director now directly owns 172,162 shares of the company's stock, valued at approximately $12,784,750.12. This trade represents a 2.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul V. Woolway sold 3,380 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $79.32, for a total value of $268,101.60. Following the sale, the insider now directly owns 57,818 shares of the company's stock, valued at $4,586,123.76. The trade was a 5.52% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,412 shares of company stock valued at $3,014,797. 6.30% of the stock is owned by corporate insiders.

About Charles Schwab

The Charles Schwab Corporation, together with its subsidiaries, operates as a savings and loan holding company that provides wealth management, securities brokerage, banking, asset management, custody, and financial advisory services in the United States and internationally. The company operates in two segments, Investor Services and Advisor Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.